cisplatin viability staining reagent Search Results


viability marker cell id cisplatin 198  (fluidigm)
94
fluidigm viability marker cell id cisplatin 198
Viability Marker Cell Id Cisplatin 198, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Cell-ID+Cisplatin-198Pt%E2%80%94100+%C2%B5L/pmc09135404-243-12-16
Average 94 stars, based on 1 article reviews
viability marker cell id cisplatin 198 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
cisplatin viability staining reagent  (fluidigm)
93
fluidigm cisplatin viability staining reagent
Cisplatin Viability Staining Reagent, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Cell-ID+Cisplatin/bio_rxiv__2021__11__08__467791-125-3-7
Average 93 stars, based on 1 article reviews
cisplatin viability staining reagent - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
cisplatin solution  (Enzo Biochem)
90
Enzo Biochem cisplatin solution
Cisplatin Solution, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/cisplatin/pmc09208434-104-11-13
Average 90 stars, based on 1 article reviews
cisplatin solution - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
a 100 μm cisplatin solution  (Enzo Biochem)
90
Enzo Biochem a 100 μm cisplatin solution
A 100 μm Cisplatin Solution, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/25+mm+cisplatin/pmc07843226-446-16-18
Average 90 stars, based on 1 article reviews
a 100 μm cisplatin solution - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
viability marker cisplatin  (fluidigm)
94
fluidigm viability marker cisplatin

Viability Marker Cisplatin, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Cell-ID+Cisplatin-194Pt/pmc06942518-266-31-35
Average 94 stars, based on 1 article reviews
viability marker cisplatin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
s1237 cisplatin cddp selleckchem  (Selleck Chemicals)
96
Selleck Chemicals s1237 cisplatin cddp selleckchem
Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or <t>cisplatin</t> <t>(CDDP)</t> at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
S1237 Cisplatin Cddp Selleckchem, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Cisplatin/pm40513578-256-167-170
Average 96 stars, based on 1 article reviews
s1237 cisplatin cddp selleckchem - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
natural abundance cisplatin viability staining reagent alx-400-040  (Enzo Biochem)
90
Enzo Biochem natural abundance cisplatin viability staining reagent alx-400-040
Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or <t>cisplatin</t> <t>(CDDP)</t> at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
Natural Abundance Cisplatin Viability Staining Reagent Alx 400 040, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Pyrrolidinedithiocarbamic+acid++PDTC+++Cat++No++ALX+400+002/pm40505659-492-8-14
Average 90 stars, based on 1 article reviews
natural abundance cisplatin viability staining reagent alx-400-040 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
non-esterified free fatty acids (nefa/ffa) colorimetric assay kit  (Guangzhou JET Bio-Filtration)
93
Guangzhou JET Bio-Filtration non-esterified free fatty acids (nefa/ffa) colorimetric assay kit
Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or <t>cisplatin</t> <t>(CDDP)</t> at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
Non Esterified Free Fatty Acids (Nefa/Ffa) Colorimetric Assay Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Non-esterified+Free+Fatty+Acids+(NEFA%2FFFA)+Colorimetric+Assay+Kit/custom%40e-bc-k013-s%4036639590
Average 93 stars, based on 1 article reviews
non-esterified free fatty acids (nefa/ffa) colorimetric assay kit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
triglyceride (tg) colorimetric assay kit (single reagent  (Guangzhou JET Bio-Filtration)
95
Guangzhou JET Bio-Filtration triglyceride (tg) colorimetric assay kit (single reagent
Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or <t>cisplatin</t> <t>(CDDP)</t> at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
Triglyceride (Tg) Colorimetric Assay Kit (Single Reagent, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/Triglyceride+(TG)+Colorimetric+Assay+Kit+(Single+Reagent/custom%40e-bc-k261-m%4036639590
Average 95 stars, based on 1 article reviews
triglyceride (tg) colorimetric assay kit (single reagent - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
cisplatin  (FUJIFILM)
90
FUJIFILM cisplatin
Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or <t>cisplatin</t> <t>(CDDP)</t> at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
Cisplatin, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cisplatin+viability+staining+reagent/cisplatin/pm39504967-235-163-164
Average 90 stars, based on 1 article reviews
cisplatin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell reports

Article Title: Molecular Signatures of Dengue Virus-Specific IL-10/IFN-γ Co-producing CD4 T Cells and Their Association with Dengue Disease

doi: 10.1016/j.celrep.2019.11.098

Figure Lengend Snippet:

Article Snippet: PBMCs were stimulated with DENV MP (1 μg/ml for individual peptides) in the presence of brefeldin A (GolgiPlug, BD Biosciences, catalog# 51–2301KZ) for 6 h. Cells were then stained with the viability marker Cisplatin (194Pt, Fluidigm, catalog# 201194) followed by a surface antibody cocktail.

Techniques: Recombinant, Staining, Activation Assay, Software

Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: Passaging, In Vitro, Injection, Control, Sequencing, In Vivo

Figure 3. Cancer cells primed with CDDP-TMZ are immunogenic in syngeneic mice models of colorectal and breast cancer (A) Average of tumor volumes (mm 3 ) ± SEM from unprimed, CDDP-TMZ-primed, and FOLFOXIRI-primed CT26 cells grown in immunodeficient (NODSCID) mice. Each experimental group included at least 8 animals. (B) Average of tumor volumes (mm 3 ) ± SEM from unprimed, CDDP-TMZ-primed, and FOLFOXIRI-primed CT26 injected in immunocompetent (BALB/c) mice. Each experimental group included at least 10 animals. (C and D) Survival curves for unprimed and primed tumors in immunodeficient (C) and immunocompetent mice (D). (E and F) Tumor volumes derived from unprimed (E) and CDDP-TMZ-primed (F) TS/A injected orthotopically in the mammary fat pad of syngeneic immuno- competent (BALB/c) mice. A total of 1 × 10 5 unprimed or primed TS/A cells were injected 1:1 in PBS:Matrigel. Treatment with anti-PD-1 (aPD-1, dashed vertical lines) was started when all tumors were palpable. Tumor growth was monitored three times per week and reported in the graph as average of tumor volumes (mm 3 ) ± SEM. Each experimental group included at least 7 animals. (G and H) Survival analyses of unprimed (G) or CDDP-TMZ-primed (H) TS/A tumors treated with anti-PD-1. Statistical significance evaluated by Mann-Whitney (A, B, E, and F) and log rank (C, D, G, and H) tests; ns, not significant (p ≥ 0.05); **p < 0.01; ***p < 0.001; and ****p < 0.0001. See also Figures S3 and S4.

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 3. Cancer cells primed with CDDP-TMZ are immunogenic in syngeneic mice models of colorectal and breast cancer (A) Average of tumor volumes (mm 3 ) ± SEM from unprimed, CDDP-TMZ-primed, and FOLFOXIRI-primed CT26 cells grown in immunodeficient (NODSCID) mice. Each experimental group included at least 8 animals. (B) Average of tumor volumes (mm 3 ) ± SEM from unprimed, CDDP-TMZ-primed, and FOLFOXIRI-primed CT26 injected in immunocompetent (BALB/c) mice. Each experimental group included at least 10 animals. (C and D) Survival curves for unprimed and primed tumors in immunodeficient (C) and immunocompetent mice (D). (E and F) Tumor volumes derived from unprimed (E) and CDDP-TMZ-primed (F) TS/A injected orthotopically in the mammary fat pad of syngeneic immuno- competent (BALB/c) mice. A total of 1 × 10 5 unprimed or primed TS/A cells were injected 1:1 in PBS:Matrigel. Treatment with anti-PD-1 (aPD-1, dashed vertical lines) was started when all tumors were palpable. Tumor growth was monitored three times per week and reported in the graph as average of tumor volumes (mm 3 ) ± SEM. Each experimental group included at least 7 animals. (G and H) Survival analyses of unprimed (G) or CDDP-TMZ-primed (H) TS/A tumors treated with anti-PD-1. Statistical significance evaluated by Mann-Whitney (A, B, E, and F) and log rank (C, D, G, and H) tests; ns, not significant (p ≥ 0.05); **p < 0.01; ***p < 0.001; and ****p < 0.0001. See also Figures S3 and S4.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: Injection, Derivative Assay, MANN-WHITNEY

Figure 4. Rejection of CDDP-TMZ-primed tumors is mediated by CD8 + T cells and elicits immunological memory (A) Graphical summary for CD8 + and/or CD4 + T cell depletion experiment. A total of 5 × 10 5 CDDP-TMZ-primed CT26 cells were injected subcutaneously in the right flank of each immunocompetent (BALB/c) mouse. Mice were randomized into 4 treatment groups: control (CTRL) receiving only the vehicle, CD8 + T cell depletion (aCD8) receiving murine anti-CD8a antibody, CD4 + T cell depletion (aCD4) receiving murine anti-CD4 antibody, and CD8 + and CD4 + T cell depletion receiving both murine aCD8 and aCD4 antibodies. (B and C) Tumor growth of CDDP-TMZ-primed CT26 tumors upon T cell depletion. (B) Average of mice tumor volumes (mm 3 ) ± SEM; statistical significance evaluated by Mann-Whitney test: ****p < 0.001. (C) Single tumor volumes from (B). (D) Effect of unprimed CT26 rechallenge in immunocompetent mice that previously rejected CDDP-TMZ-primed tumors. Subsequent inoculation of CT26 un- primed or primed with single agent TMZ or CDDP (red arrow) in previously challenged (vaccinated) BALB/c mice (corresponding to tumor-free mice from Figure 3B), compared with naive BALB/c mice; n = 10 in vaccinated BALB/c group, n = 5 in naive BALB/c group. See also Figure S5.

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 4. Rejection of CDDP-TMZ-primed tumors is mediated by CD8 + T cells and elicits immunological memory (A) Graphical summary for CD8 + and/or CD4 + T cell depletion experiment. A total of 5 × 10 5 CDDP-TMZ-primed CT26 cells were injected subcutaneously in the right flank of each immunocompetent (BALB/c) mouse. Mice were randomized into 4 treatment groups: control (CTRL) receiving only the vehicle, CD8 + T cell depletion (aCD8) receiving murine anti-CD8a antibody, CD4 + T cell depletion (aCD4) receiving murine anti-CD4 antibody, and CD8 + and CD4 + T cell depletion receiving both murine aCD8 and aCD4 antibodies. (B and C) Tumor growth of CDDP-TMZ-primed CT26 tumors upon T cell depletion. (B) Average of mice tumor volumes (mm 3 ) ± SEM; statistical significance evaluated by Mann-Whitney test: ****p < 0.001. (C) Single tumor volumes from (B). (D) Effect of unprimed CT26 rechallenge in immunocompetent mice that previously rejected CDDP-TMZ-primed tumors. Subsequent inoculation of CT26 un- primed or primed with single agent TMZ or CDDP (red arrow) in previously challenged (vaccinated) BALB/c mice (corresponding to tumor-free mice from Figure 3B), compared with naive BALB/c mice; n = 10 in vaccinated BALB/c group, n = 5 in naive BALB/c group. See also Figure S5.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: Injection, Control, MANN-WHITNEY

Figure 5. Immunoediting of chemotherapy-induced mutations and neoantigens preferentially involves CDDP-TMZ primed tumors (A) Graphical summary: mutations emerging after in vitro priming phase were monitored in tumors grown in immunodeficient and immunocompetent syngeneic mice. Mutations retained in both in vivo models are listed as immune neutral, whereas mutations maintained in tumors grown in immunodeficient mice and negatively selected in immunocompetent mice are indicated as immunoedited. (B) Distribution of immunoedited and immune neutral chemotherapy-induced mutations from single tumors grown in immunocompetent mice across the tested priming treatments (unprimed, TMZ single agent, CDDP single agent, CDDP-TMZ combination, and FOLFOXIRI combination). (C) Relative distribution of SBS31 and SBS11 in immune neutral and immunoedited groups of mutations consistently found across replicates. (D) Relative distribution of expressed acquired neoantigens undergoing immune selection, filtered for expression levels >10 FPKM. Results represent the ne- oantigens consistently found across replicates (n = 3 tumors from NODSCID mice and n = 4 and 5 for unprimed and CDDP-TMZ-primed tumors grown in BALB/c mice, respectively) for each condition. (E) Distribution of the allelic frequency of the mutations (variant allelic frequency, VAF) associated to expressed (FPKM >10) predicted neoantigens consistently found across replicates (n = 3 tumors from NODSCID mice and n = 4 and 5 for unprimed and CDDP-TMZ-primed tumors grown in BALB/c mice, respectively). Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers). Statistical significance evaluated by Mann-Whitney test: ***p < 0.001. See also Figure S6, and Tables S1 and S2.

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 5. Immunoediting of chemotherapy-induced mutations and neoantigens preferentially involves CDDP-TMZ primed tumors (A) Graphical summary: mutations emerging after in vitro priming phase were monitored in tumors grown in immunodeficient and immunocompetent syngeneic mice. Mutations retained in both in vivo models are listed as immune neutral, whereas mutations maintained in tumors grown in immunodeficient mice and negatively selected in immunocompetent mice are indicated as immunoedited. (B) Distribution of immunoedited and immune neutral chemotherapy-induced mutations from single tumors grown in immunocompetent mice across the tested priming treatments (unprimed, TMZ single agent, CDDP single agent, CDDP-TMZ combination, and FOLFOXIRI combination). (C) Relative distribution of SBS31 and SBS11 in immune neutral and immunoedited groups of mutations consistently found across replicates. (D) Relative distribution of expressed acquired neoantigens undergoing immune selection, filtered for expression levels >10 FPKM. Results represent the ne- oantigens consistently found across replicates (n = 3 tumors from NODSCID mice and n = 4 and 5 for unprimed and CDDP-TMZ-primed tumors grown in BALB/c mice, respectively) for each condition. (E) Distribution of the allelic frequency of the mutations (variant allelic frequency, VAF) associated to expressed (FPKM >10) predicted neoantigens consistently found across replicates (n = 3 tumors from NODSCID mice and n = 4 and 5 for unprimed and CDDP-TMZ-primed tumors grown in BALB/c mice, respectively). Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers). Statistical significance evaluated by Mann-Whitney test: ***p < 0.001. See also Figure S6, and Tables S1 and S2.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: Immunopeptidomics, In Vitro, In Vivo, Selection, Expressing, Variant Assay, MANN-WHITNEY

Figure 6. Two cycles of in vivo chemotherapy induce a remodeling of the tumor immune microenvironment (A) Experimental workflow: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected into the flank of immunocompetent mice. On day 6, when the average tumor volume was 60–100 mm 3 , mice were randomized into 5 treatment groups: CTRL (saline vehicle), TMZ (20 mg/kg day-1-5 weekly), CDDP (5 mg/kg day 1 weekly), TMZ + CDDP, and FOLFOXIRI (5FU 25 mg/kg day 1, oxaliplatin 3 mg/kg day 1, irinotecan 25 mg/kg day 1, weekly). After two weeks of treatment, tumors were harvested, dissociated into single cell suspensions, and immunostained for flow cytometry analysis. Each tumor suspension was analyzed using spectral flow cytometry and results were elaborated using an unbiased bioinformatic pipeline (see STAR Methods). (B) Average tumor volume ± SEM of tumors treated with chemotherapy in vivo. The vertical red dotted line indicates day 1 of each chemotherapy cycle. Statistical significance evaluated by Mann-Whitney test; ns, not significant (p ≥ 0.05); *p < 0.05. (C) Relative average distribution of the 23 immune clusters across the treatment arms. (D–J) Distribution of relevant immune populations across the different experimental arms. Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers) of the percentage of the specific cluster in each analyzed tumor (n = 10 tumors/condition). (D) Distribution of total NK cells over CD45 + cells (clusters 7–9); (E) cytotoxic NK cells over CD45 + cells (perforin positive, clusters 7 and 9); (F) relative abundance of

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 6. Two cycles of in vivo chemotherapy induce a remodeling of the tumor immune microenvironment (A) Experimental workflow: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected into the flank of immunocompetent mice. On day 6, when the average tumor volume was 60–100 mm 3 , mice were randomized into 5 treatment groups: CTRL (saline vehicle), TMZ (20 mg/kg day-1-5 weekly), CDDP (5 mg/kg day 1 weekly), TMZ + CDDP, and FOLFOXIRI (5FU 25 mg/kg day 1, oxaliplatin 3 mg/kg day 1, irinotecan 25 mg/kg day 1, weekly). After two weeks of treatment, tumors were harvested, dissociated into single cell suspensions, and immunostained for flow cytometry analysis. Each tumor suspension was analyzed using spectral flow cytometry and results were elaborated using an unbiased bioinformatic pipeline (see STAR Methods). (B) Average tumor volume ± SEM of tumors treated with chemotherapy in vivo. The vertical red dotted line indicates day 1 of each chemotherapy cycle. Statistical significance evaluated by Mann-Whitney test; ns, not significant (p ≥ 0.05); *p < 0.05. (C) Relative average distribution of the 23 immune clusters across the treatment arms. (D–J) Distribution of relevant immune populations across the different experimental arms. Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers) of the percentage of the specific cluster in each analyzed tumor (n = 10 tumors/condition). (D) Distribution of total NK cells over CD45 + cells (clusters 7–9); (E) cytotoxic NK cells over CD45 + cells (perforin positive, clusters 7 and 9); (F) relative abundance of

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: In Vivo, Injection, Saline, Flow Cytometry, Suspension, MANN-WHITNEY

Figure 7. In vivo concomitant treatment with CDDP and TMZ is immunogenic and induces complete regressions in combination with anti- PD-1 (A) Graphical summary: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected in the flank of immunocompetent mice until establishment of measurable tumors (average volume >50 mm 3 ). After that, mice were randomized in 4 groups: vehicle (CTRL), anti-PD-1 (aPD-1), chemotherapy (CDDP+TMZ), and immunotherapy + chemotherapy (aPD-1+CDDP+TMZ). (B and C) Tumor growth of naive CT26-derived tumors treated in vivo with aPD-1, chemotherapy (CDDP+TMZ), or their combination (aPD-1+CDDP+TMZ). (B) Average of tumor volumes (mm 3 ) ± SEM. (C) Individual tumor volumes. CDDP was administered intraperitoneally (i.p.) at 5 mg/kg once a week (vertical red dotted line), TMZ was administered i.p. for 5 consecutive days a week at 20 mg/kg, starting the same day as CDDP (vertical red dotted line) for a total of 2 weeks. Anti- PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). (D and E) Tumor growth of naive CT26-derived tumors treated in vivo with chemotherapy (FOLFOXIRI), or its combination with aPD-1 (aPD-1+FOLFOXIRI). (D) Average of tumor volumes (mm 3 ) ± SEM. (E) Individual tumor volumes. Chemotherapy (5FU 25 mg/kg, Oxa 3 mg/kg, irinotecan 25 mg/kg) was administered i.p. once a week once a week (vertical red dotted line) for a total of 2 weeks, anti-PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). Statistical significance was evaluated by Mann-Whitney test (B and D); ns, not significant (p ≥ 0.05); * p < 0.05; and **p < 0.01. Each experimental group included at least 6 animals. See also Figure S8.

Journal: Cancer cell

Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

doi: 10.1016/j.ccell.2025.05.014

Figure Lengend Snippet: Figure 7. In vivo concomitant treatment with CDDP and TMZ is immunogenic and induces complete regressions in combination with anti- PD-1 (A) Graphical summary: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected in the flank of immunocompetent mice until establishment of measurable tumors (average volume >50 mm 3 ). After that, mice were randomized in 4 groups: vehicle (CTRL), anti-PD-1 (aPD-1), chemotherapy (CDDP+TMZ), and immunotherapy + chemotherapy (aPD-1+CDDP+TMZ). (B and C) Tumor growth of naive CT26-derived tumors treated in vivo with aPD-1, chemotherapy (CDDP+TMZ), or their combination (aPD-1+CDDP+TMZ). (B) Average of tumor volumes (mm 3 ) ± SEM. (C) Individual tumor volumes. CDDP was administered intraperitoneally (i.p.) at 5 mg/kg once a week (vertical red dotted line), TMZ was administered i.p. for 5 consecutive days a week at 20 mg/kg, starting the same day as CDDP (vertical red dotted line) for a total of 2 weeks. Anti- PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). (D and E) Tumor growth of naive CT26-derived tumors treated in vivo with chemotherapy (FOLFOXIRI), or its combination with aPD-1 (aPD-1+FOLFOXIRI). (D) Average of tumor volumes (mm 3 ) ± SEM. (E) Individual tumor volumes. Chemotherapy (5FU 25 mg/kg, Oxa 3 mg/kg, irinotecan 25 mg/kg) was administered i.p. once a week once a week (vertical red dotted line) for a total of 2 weeks, anti-PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). Statistical significance was evaluated by Mann-Whitney test (B and D); ns, not significant (p ≥ 0.05); * p < 0.05; and **p < 0.01. Each experimental group included at least 6 animals. See also Figure S8.

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

Techniques: In Vivo, Injection, Derivative Assay, MANN-WHITNEY